NEWS・COLUMN
We send the latest information from SMC Laboratories.
Study on the efficacy of dietary supplements in the STAM™ model published in Cell Death & Disease.
SMC is proud to announce that J2H biotech (KOR) has published the results of their study using our pre-clinical services with STAM™ model in Cell Death & Disease. Title: Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH (Lee et al., Cell Death Dis . 2022) This…
Introduction of STAM™ model for pre-clinical studies for liver cancer
Today, we give you a brief introduction to our proprietary NASH-HCC model (STAM™ model). The STAM™ model was originally developed as a NASH model, but with a 100% incidence of hepatocellular carcinoma (HCC) as early as 20 weeks of age, it is also an excellent platform for oncology research and therapeutic development. The model…
Study on the efficacy of dietary supplements in the STAM™ model published in BMJ Open Gastroenterology
SMC is proud to announce that GN Corporation Co. Ltd (JPN) has published the results of their study using our STAM™ model in BMJ Open Gastroenterology. In this study, the authors observed how two β-glucans derived from the AFO-202 and N-163 strains of black yeast, Aureobasidium pullulans, affected the gut microbiota and fecal metabolome…
Drug Efficacy Study in the STAM™ Model Published in Biomedicines.
SMC is proud to announce that MRM Health (BEL) has published the results of their study using our STAM™ model in Biomedicines. ■Title A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo (Pinheiro et al., Biomedicines. 2022) The above study tested the therapeutic effects of a…
Introducing our new skin disease model: Imiquimod (IMQ)-induced psoriasis model
We are pleased to announce that we have expanded our preclinical model lineup by including the “Imiquimod (IMQ)-induced dermatitis model” for psoriasis. Psoriasis is a refractory skin disease that is caused by both genetic and environmental factors. It causes chronic inflammation characterized by the clinical appearance of erythema and scaling of the skin….
Introduction of MAFLD criteria and the disease model
Today, we would like to introduce metabolic dysfunction-associated fatty liver disease (MAFLD), a new concept in the study of fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is defined as the presence of fatty liver disease in the absence of any known causes of steatosis. The number of NAFLD cases are growing worldwide due…
SMC client receives award for presentation on study of NASH diagnosis at 40th annual meeting of JSLSM
Today, I would like to share with you some wonderful and exciting news! Recently, a client of ours from the National Defense Medical College, Dr. Yasuhiro Takihata, gave a presentation on NASH diagnostics at the 40th Annual Meeting of the Japanese Society of Laser Medicine (JSLSM) and was awarded the Annual Meeting Award for his…
Introduction of our Primary sclerosing cholangitis (PSC) mice model
Today, I would like to give you a brief introduction into primary sclerosing cholangitis (PSC), as well as our 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine (DDC) mouse model. PSC is a rare, chronic cholestatic liver disease characterized by biliary inflammation that develops into fibrosis and causes intrahepatic and/or extrahepatic bile duct strictures.These strictures impede bile flow within the ducts…
The effect of the gut-liver axis dysfunction in liver disease
Today, I would like to introduce the relationship between Nonalcoholic steatohepatitis (NASH) and the gut. Factors contributing to the progression of the NASH include oxidative stress, lipotoxicity, and mitochondrial dysfunction, and recently much attention has been focused on gut-liver axis dysfunction. The gut and the liver are connected by a blood vessel called…
Drug Efficacy Study in the STAM™ Model Published in Cells
SMC is proud to announce that Cellaïon (BEL) has published the results of their study using our STAM™ model in Cells. ■Title Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model ( Najimi et al., Cells. 2022 ) In this study, the authors reported that…
Drug Efficacy Study in the STAM™ Model Published in Gene
SMC is proud to announce that TSUMURA & CO. (JPN) has published the results of their study using our STAM™ model in Gene. ■Title Integrated analysis of effect of daisaikoto, a traditional Japanese medicine, on the metabolome and gut microbiome in a mouse model of nonalcoholic fatty liver disease Ishizawa et al., Gene. 2022…
SMC participate The BioJapan Partnering!
We are pleased to announce that SMC Laboratories will be participating the BioJapan Partnering Event from October 12th (Wed) to 14th (Fri). BioJapan is Asia’s largest partnering event and offers attendees the opportunity to partake in many different exhibitions, seminars, and partnering programs, as well as hold face-to-face meetings at on-site exhibition booths. We would…